3,4-Diaminopyridine

(from PubChem) Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations. It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambert-Eaton myasthenic syndrome (LEMS), has been investigated in the 1980s Patients with LEMS develop serum antibodies against presynaptic P\/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine. Used for treatment Botulinum neurotoxin: nature's deadliest biomolecule.

General

Type : Pyridine, Calcium Channel Antagonist

Chemical_Nomenclature :

Canonical SMILES :

InChI :

InChIKey :

Other name(s) : pyridine-3,4-diamine || Amifampridine || Firdapse || 3,4-Pyridinediamine || 3,4-DAP || CHEMBL354077 || SCHEMBL21273 || CHEBI:135948 || ZINC164000


MW : 109.13

Formula : C5H7N3

CAS_number : 54-96-6

PubChem : 5918

Target

Families : No family

Protein : No protein

References (38)

Title : Therapeutic strategies for congenital myasthenic syndromes - Lee_2018_Ann.N.Y.Acad.Sci_1412_129
Author(s) : Lee M , Beeson D , Palace J
Ref : Annals of the New York Academy of Sciences , 1412 :129 , 2018
Abstract : Lee_2018_Ann.N.Y.Acad.Sci_1412_129
ESTHER : Lee_2018_Ann.N.Y.Acad.Sci_1412_129
PubMedSearch : Lee_2018_Ann.N.Y.Acad.Sci_1412_129
PubMedID: 29381222

Title : 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies -
Author(s) : Evoli A , Alboini PE , Damato V , Iorio R
Ref : Neurology , 86 :1070 , 2016
PubMedID: 26873957

Title : The Facilitatory Effect of Casearia sylvestris Sw. (guacatonga) Fractions on the Contractile Activity of Mammalian and Avian Neuromuscular Apparatus - Werner_2015_Curr.Pharm.Biotechnol_16_468
Author(s) : Werner AC , Ferraz MC , Yoshida EH , Tribuiani N , Gautuz JA , Santana MN , Dezzotti BA , de Miranda VG , Foramiglio AL , Rostelato-Ferreira S , Tavares RV , Hyslop S , Oshima-Franco Y
Ref : Curr Pharm Biotechnol , 16 :468 , 2015
Abstract : Werner_2015_Curr.Pharm.Biotechnol_16_468
ESTHER : Werner_2015_Curr.Pharm.Biotechnol_16_468
PubMedSearch : Werner_2015_Curr.Pharm.Biotechnol_16_468
PubMedID: 25751174

Title : The European LEMS Registry: Baseline Demographics and Treatment Approaches - Mantegazza_2015_Neurol.Ther_4_105
Author(s) : Mantegazza R , Meisel A , Sieb JP , Le Masson G , Desnuelle C , Essing M
Ref : Neurol Ther , 4 :105 , 2015
Abstract : Mantegazza_2015_Neurol.Ther_4_105
ESTHER : Mantegazza_2015_Neurol.Ther_4_105
PubMedSearch : Mantegazza_2015_Neurol.Ther_4_105
PubMedID: 26525537

Title : Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism - Gable_2015_Semin.Neurol_35_340
Author(s) : Gable KL , Massey JM
Ref : Semin Neurol , 35 :340 , 2015
Abstract : Gable_2015_Semin.Neurol_35_340
ESTHER : Gable_2015_Semin.Neurol_35_340
PubMedSearch : Gable_2015_Semin.Neurol_35_340
PubMedID: 26502758

Title : Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate - Haroldsen_2015_Pharmacol.Res.Perspect_3_e00099
Author(s) : Haroldsen PE , Garovoy MR , Musson DG , Zhou H , Tsuruda L , Hanson B , O'Neill CA
Ref : Pharmacol Res Perspect , 3 :e00099 , 2015
Abstract : Haroldsen_2015_Pharmacol.Res.Perspect_3_e00099
ESTHER : Haroldsen_2015_Pharmacol.Res.Perspect_3_e00099
PubMedSearch : Haroldsen_2015_Pharmacol.Res.Perspect_3_e00099
PubMedID: 25692017

Title : Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome - Witting_2014_JAMA.Neurol_71_350
Author(s) : Witting N , Vissing J
Ref : JAMA Neurol , 71 :350 , 2014
Abstract : Witting_2014_JAMA.Neurol_71_350
ESTHER : Witting_2014_JAMA.Neurol_71_350
PubMedSearch : Witting_2014_JAMA.Neurol_71_350
PubMedID: 24425145

Title : 3,4-Diaminopyridine may improve neuromuscular block during botulism -
Author(s) : Friggeri A , Marcon F , Marciniak S , Lemaire-Hurtel AS , Seydi A , Ammenouche N , Levrard M , Mahjoub Y , Airapetian N , Tinturier F , Petitjean M , Dupont H
Ref : Crit Care , 17 :449 , 2013
PubMedID: 24007658

Title : Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody - Morsch_2013_J.Physiol_591_2747
Author(s) : Morsch M , Reddel SW , Ghazanfari N , Toyka KV , Phillips WD
Ref : The Journal of Physiology , 591 :2747 , 2013
Abstract : Morsch_2013_J.Physiol_591_2747
ESTHER : Morsch_2013_J.Physiol_591_2747
PubMedSearch : Morsch_2013_J.Physiol_591_2747
PubMedID: 23440963

Title : 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis - Mori_2012_J.Neuroimmunol_245_75
Author(s) : Mori S , Kishi M , Kubo S , Akiyoshi T , Yamada S , Miyazaki T , Konishi T , Maruyama N , Shigemoto K
Ref : Journal of Neuroimmunology , 245 :75 , 2012
Abstract : Mori_2012_J.Neuroimmunol_245_75
ESTHER : Mori_2012_J.Neuroimmunol_245_75
PubMedSearch : Mori_2012_J.Neuroimmunol_245_75
PubMedID: 22409941

Title : Recurrent COLQ mutation in congenital myasthenic syndrome - Guven_2012_Pediatr.Neurol_46_253
Author(s) : Guven A , Demirci M , Anlar B
Ref : Pediatr Neurol , 46 :253 , 2012
Abstract : Guven_2012_Pediatr.Neurol_46_253
ESTHER : Guven_2012_Pediatr.Neurol_46_253
PubMedSearch : Guven_2012_Pediatr.Neurol_46_253
PubMedID: 22490774

Title : Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine - Lindquist_2011_Neuropsychiatr.Dis.Treat_7_341
Author(s) : Lindquist S , Stangel M
Ref : Neuropsychiatr Dis Treat , 7 :341 , 2011
Abstract : Lindquist_2011_Neuropsychiatr.Dis.Treat_7_341
ESTHER : Lindquist_2011_Neuropsychiatr.Dis.Treat_7_341
PubMedSearch : Lindquist_2011_Neuropsychiatr.Dis.Treat_7_341
PubMedID: 21822385

Title : Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations - Sadeh_2011_Muscle.Nerve_44_289
Author(s) : Sadeh M , Shen XM , Engel AG
Ref : Muscle & Nerve , 44 :289 , 2011
Abstract : Sadeh_2011_Muscle.Nerve_44_289
ESTHER : Sadeh_2011_Muscle.Nerve_44_289
PubMedSearch : Sadeh_2011_Muscle.Nerve_44_289
PubMedID: 21721016

Title : Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization - Zakhari_2011_Bioorg.Med.Chem_19_6203
Author(s) : Zakhari JS , Kinoyama I , Hixon MS , Di Mola A , Globisch D , Janda KD
Ref : Bioorganic & Medicinal Chemistry , 19 :6203 , 2011
Abstract : Zakhari_2011_Bioorg.Med.Chem_19_6203
ESTHER : Zakhari_2011_Bioorg.Med.Chem_19_6203
PubMedSearch : Zakhari_2011_Bioorg.Med.Chem_19_6203
PubMedID: 21975066

Title : The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia - Tsunemi_2010_J.Neurol.Sci_292_81
Author(s) : Tsunemi T , Ishikawa K , Tsukui K , Sumi T , Kitamura K , Mizusawa H
Ref : Journal of Neurology Sci , 292 :81 , 2010
Abstract : Tsunemi_2010_J.Neurol.Sci_292_81
ESTHER : Tsunemi_2010_J.Neurol.Sci_292_81
PubMedSearch : Tsunemi_2010_J.Neurol.Sci_292_81
PubMedID: 20181362

Title : 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome - Wirtz_2010_Expert.Rev.Clin.Immunol_6_867
Author(s) : Wirtz PW , Titulaer MJ , Gerven JM , Verschuuren JJ
Ref : Expert Rev Clin Immunol , 6 :867 , 2010
Abstract : Wirtz_2010_Expert.Rev.Clin.Immunol_6_867
ESTHER : Wirtz_2010_Expert.Rev.Clin.Immunol_6_867
PubMedSearch : Wirtz_2010_Expert.Rev.Clin.Immunol_6_867
PubMedID: 20979551

Title : [Treatment approach to congenital myasthenic syndrome in a patient with acetylcholine receptor deficiency] - Ishigaki_2009_No.To.Hattatsu_41_37
Author(s) : Ishigaki K , Murakami T , Ito Y , Yanagisawa A , Kodaira K , Shishikura K , Suzuki H , Hirayama Y , Osawa M
Ref : No To Hattatsu , 41 :37 , 2009
Abstract : Ishigaki_2009_No.To.Hattatsu_41_37
ESTHER : Ishigaki_2009_No.To.Hattatsu_41_37
PubMedSearch : Ishigaki_2009_No.To.Hattatsu_41_37
PubMedID: 19172815

Title : Therapeutic strategies in congenital myasthenic syndromes - Schara_2008_Neurotherapeutics_5_542
Author(s) : Schara U , Lochmuller H
Ref : Neurotherapeutics , 5 :542 , 2008
Abstract : Schara_2008_Neurotherapeutics_5_542
ESTHER : Schara_2008_Neurotherapeutics_5_542
PubMedSearch : Schara_2008_Neurotherapeutics_5_542
PubMedID: 19019305

Title : Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine - Banwell_2004_Neuromuscul.Disord_14_202
Author(s) : Banwell BL , Ohno K , Sieb JP , Engel AG
Ref : Neuromuscular Disorders , 14 :202 , 2004
Abstract : Banwell_2004_Neuromuscul.Disord_14_202
ESTHER : Banwell_2004_Neuromuscul.Disord_14_202
PubMedSearch : Banwell_2004_Neuromuscul.Disord_14_202
PubMedID: 15036330

Title : Improvement of dy\/dy dystrophic diaphragm by 3,4-diaminopyridine - van Lunteren_2002_Muscle.Nerve_26_71
Author(s) : van Lunteren E , Moyer M
Ref : Muscle & Nerve , 26 :71 , 2002
Abstract : van Lunteren_2002_Muscle.Nerve_26_71
ESTHER : van Lunteren_2002_Muscle.Nerve_26_71
PubMedSearch : van Lunteren_2002_Muscle.Nerve_26_71
PubMedID: 12115951

Title : 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome - Molgo_1996_Pflugers.Arch_431_R295
Author(s) : Molgo J , Guglielmi JM
Ref : Pflugers Arch , 431 :R295 , 1996
Abstract : Molgo_1996_Pflugers.Arch_431_R295
ESTHER : Molgo_1996_Pflugers.Arch_431_R295
PubMedSearch : Molgo_1996_Pflugers.Arch_431_R295
PubMedID: 8739381

Title : Physostigmine, but not 3,4-diaminopyridine, improves radial maze performance in memory-impaired rats - Beninger_1995_Pharmacol.Biochem.Behav_51_739
Author(s) : Beninger RJ , Wirsching BA , Mallet PE , Jhamandas K , Boegman RJ
Ref : Pharmacol Biochem Behav , 51 :739 , 1995
Abstract : Beninger_1995_Pharmacol.Biochem.Behav_51_739
ESTHER : Beninger_1995_Pharmacol.Biochem.Behav_51_739
PubMedSearch : Beninger_1995_Pharmacol.Biochem.Behav_51_739
PubMedID: 7675853

Title : Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine - Russell_1995_Mayo.Clin.Proc_70_532
Author(s) : Russell JW , Windebank AJ , Harper CM, Jr.
Ref : Mayo Clin Proc , 70 :532 , 1995
Abstract : Russell_1995_Mayo.Clin.Proc_70_532
ESTHER : Russell_1995_Mayo.Clin.Proc_70_532
PubMedSearch : Russell_1995_Mayo.Clin.Proc_70_532
PubMedID: 7776711

Title : 3,4-Diaminopyridine and choline increase in vivo acetylcholine release in rat striatum - Buyukuysal_1995_Eur.J.Pharmacol_281_179
Author(s) : Buyukuysal RL , Ulus IH , Aydin S , Kiran BK
Ref : European Journal of Pharmacology , 281 :179 , 1995
Abstract : Buyukuysal_1995_Eur.J.Pharmacol_281_179
ESTHER : Buyukuysal_1995_Eur.J.Pharmacol_281_179
PubMedSearch : Buyukuysal_1995_Eur.J.Pharmacol_281_179
PubMedID: 7589205

Title : 3,4-Diaminopyridine facilitates norepinephrine release in chick sympathetic neurons - Huang_1995_Zhongguo.Yao.Li.Xue.Bao_16_348
Author(s) : Huang HY , Zhou CW
Ref : Zhongguo Yao Li Xue Bao , 16 :348 , 1995
Abstract : Huang_1995_Zhongguo.Yao.Li.Xue.Bao_16_348
ESTHER : Huang_1995_Zhongguo.Yao.Li.Xue.Bao_16_348
PubMedSearch : Huang_1995_Zhongguo.Yao.Li.Xue.Bao_16_348
PubMedID: 7668108

Title : 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis - Polman_1994_Arch.Neurol_51_1136
Author(s) : Polman CH , Bertelsmann FW , de Waal R , van Diemen HA , Uitdehaag BM , van Loenen AC , Koetsier JC
Ref : Archives of Neurology , 51 :1136 , 1994
Abstract : Polman_1994_Arch.Neurol_51_1136
ESTHER : Polman_1994_Arch.Neurol_51_1136
PubMedSearch : Polman_1994_Arch.Neurol_51_1136
PubMedID: 7980110

Title : Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro - Braga_1991_Br.J.Pharmacol_102_909
Author(s) : Braga MF , Harvey AL , Rowan EG
Ref : British Journal of Pharmacology , 102 :909 , 1991
Abstract : Braga_1991_Br.J.Pharmacol_102_909
ESTHER : Braga_1991_Br.J.Pharmacol_102_909
PubMedSearch : Braga_1991_Br.J.Pharmacol_102_909
PubMedID: 1649660

Title : Facilitation by 3,4-diaminopyridine of regenerative acetylcholine release from mouse motor nerve - Hong_1990_Br.J.Pharmacol_101_793
Author(s) : Hong SJ , Chang CC
Ref : British Journal of Pharmacology , 101 :793 , 1990
Abstract : Hong_1990_Br.J.Pharmacol_101_793
ESTHER : Hong_1990_Br.J.Pharmacol_101_793
PubMedSearch : Hong_1990_Br.J.Pharmacol_101_793
PubMedID: 1964819

Title : Effects of LF-14, THA and physostigmine in rat hippocampus and cerebral cortex - Potter_1989_Neurochem.Int_14_433
Author(s) : Potter PE , Nitta S , Chaudhry I , Lalezari I , Goldiner P , Foldes FF
Ref : Neurochem Int , 14 :433 , 1989
Abstract : Potter_1989_Neurochem.Int_14_433
ESTHER : Potter_1989_Neurochem.Int_14_433
PubMedSearch : Potter_1989_Neurochem.Int_14_433
PubMedID: 20504446

Title : Changes in cytosolic free calcium with 1,2,3,4-tetrahydro-5-aminoacridine, 4-aminopyridine and 3,4-diaminopyridine - Gibson_1988_Biochem.Pharmacol_37_4191
Author(s) : Gibson GE , Manger T
Ref : Biochemical Pharmacology , 37 :4191 , 1988
Abstract : Gibson_1988_Biochem.Pharmacol_37_4191
ESTHER : Gibson_1988_Biochem.Pharmacol_37_4191
PubMedSearch : Gibson_1988_Biochem.Pharmacol_37_4191
PubMedID: 2847755

Title : Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin - Molgo_1987_Muscle.Nerve_10_464
Author(s) : Molgo J , Lemeignan M , Thesleff S
Ref : Muscle & Nerve , 10 :464 , 1987
Abstract : Molgo_1987_Muscle.Nerve_10_464
ESTHER : Molgo_1987_Muscle.Nerve_10_464
PubMedSearch : Molgo_1987_Muscle.Nerve_10_464
PubMedID: 3497343

Title : Differential alteration of dopamine, acetylcholine, and glutamate release during anoxia and\/or 3,4-diaminopyridine treatment - Freeman_1987_Neurochem.Res_12_1019
Author(s) : Freeman GB , Mykytyn V , Gibson GE
Ref : Neurochem Res , 12 :1019 , 1987
Abstract : Freeman_1987_Neurochem.Res_12_1019
ESTHER : Freeman_1987_Neurochem.Res_12_1019
PubMedSearch : Freeman_1987_Neurochem.Res_12_1019
PubMedID: 2891059

Title : Interactions of Calcium Homeostasis, Acetylcholine Metabolism, Behavior and 3,4-Diaminopyridine during Aging -
Author(s) : Gibson GE , Peterson C
Ref : Advances in Behavioral Biology , 30 :191 , 1986
PubMedID:

Title : Spontaneous excitatory postsynaptic currents in crayfish neuromuscular junctions in the absence and presence of serotonin and 3,4-diaminopyridine - Finger_1986_J.Comp.Physiol.A_159_13
Author(s) : Finger W , Martin C
Ref : J Comp Physiol A , 159 :13 , 1986
Abstract : Finger_1986_J.Comp.Physiol.A_159_13
ESTHER : Finger_1986_J.Comp.Physiol.A_159_13
PubMedSearch : Finger_1986_J.Comp.Physiol.A_159_13
PubMedID: 3746725

Title : Amelioration of age-related neurochemical and behavioral deficits by 3,4-diaminopyridine - Peterson_1983_Neurobiol.Aging_4_25
Author(s) : Peterson C , Gibson GE
Ref : Neurobiology of Aging , 4 :25 , 1983
Abstract : Peterson_1983_Neurobiol.Aging_4_25
ESTHER : Peterson_1983_Neurobiol.Aging_4_25
PubMedSearch : Peterson_1983_Neurobiol.Aging_4_25
PubMedID: 6877484

Title : Improvement of 8-arm maze performance in aged Fischer 344 rats with 3,4-diaminopyridine - Davis_1983_Exp.Aging.Res_9_211
Author(s) : Davis HP , Idowu A , Gibson GE
Ref : Exp Aging Res , 9 :211 , 1983
Abstract : Davis_1983_Exp.Aging.Res_9_211
ESTHER : Davis_1983_Exp.Aging.Res_9_211
PubMedSearch : Davis_1983_Exp.Aging.Res_9_211
PubMedID: 6641784

Title : 3,4-diaminopyridine alters acetylcholine metabolism and behavior during hypoxia - Peterson_1982_J.Pharmacol.Exp.Ther_222_576
Author(s) : Peterson C , Gibson GE
Ref : Journal of Pharmacology & Experimental Therapeutics , 222 :576 , 1982
Abstract : Peterson_1982_J.Pharmacol.Exp.Ther_222_576
ESTHER : Peterson_1982_J.Pharmacol.Exp.Ther_222_576
PubMedSearch : Peterson_1982_J.Pharmacol.Exp.Ther_222_576
PubMedID: 6286925

Title : Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes -
Author(s) : Molgo J , Lundh H , Thesleff S
Ref : European Journal of Pharmacology , 61 :25 , 1980
PubMedID: 6101553